Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway

Human Mutation

Volumn 35, Issue 2, 2014, Pages 227-235

  Paré Brunet, Laia ^a   Glubb, Dylan ^b   Evans, Patrick ^c   Berenguer Llergo, Antoni ^d   Etheridge, Amy S ^b   Skol, Andrew D ^c   Di Rienzo, Anna ^c   Duan, Shiwei ^e   Gamazon, Eric R ^c   Innocenti, Federico ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e NINGBO UNIVERSITY   (China)

Author keywords

Angiogenesis; Expression; GWAS; Pathway; Pharmacogenetics; QTL; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; LUCIFERASE ASSAY; LYMPHOBLASTOID CELL LINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REPORTER GENE;

ANGIOGENESIS; EXPRESSION; GWAS; PATHWAY; PHARMACOGENETICS; QTL; VEGF;

AFRICAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; GENE EXPRESSION; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINKAGE DISEQUILIBRIUM; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NIGERIA; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891932404     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22475     Document Type: Article

References (54)

1. Bernatchez PN, Rollin S, Soker S, Sirois MG. 2002. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: role of neuropilin-1. J Cell Biochem 85:629-639.
2. Carr DF, Whiteley G, Alfirevic A, Pirmohamed M. 2009. Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J 9:291-305.
3. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, et al. 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68:8535-8540.
4. Chorley BN, Wang X, Campbell MR, Pittman GS, Noureddine MA, Bell DA. 2008. Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current and developing technologies. Mutat Res 659:147-157.
5. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Arcelus MG, Sekowska M, Gagnebin M, Nisbett J, et al. 2009. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325:1246-1250.
6. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. 2008a. Genetic architecture of transcript-level variation in humans. Am J Hum Genet 82:1101-1113.
7. Duan S, Zhang W, Bleibel WK, Cox NJ, Dolan ME. 2008b. SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation 2:469-470.
8. Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, Savas S, Mackay HJ, Amir E, Liu G. 2012. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res 18:4526-4537.
9. Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
10. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, et al. 2007. A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861.
11. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, Casey G, De Biasi M, Carlson C, Duggan D, James M, Liu P, et al. 2011. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 43:513-518.
12. Gil-Pisa I, Munarriz-Cuezva E, Ramos-Miguel A, Urigüen L, Meana JJ, García-Sevilla JA. 2012. Regulation of munc18-1 and syntaxin-1A interactive partners in schizophrenia prefrontal cortex: down-regulation of munc18-1a isoform and 75 kDa SNARE complex after antipsychotic treatment. Int J Neuropsychopharmacol 15:573-588.
13. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, et al. 2011. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17:5257-5267.
14. Glubb DM, Innocenti F. 2011. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med 3:299-313.
15. Gordon D, Abajian C, Green P. 1998. Consed: a graphical tool for sequence finishing. Genome Res 8:195-202.
16. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, et al. 2010. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 10:458-464.
17. Green ED, Guyer MS. 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470:204-213.
18. Hicklin DJ, Ellis LM. 2005a. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027.
19. Hicklin DJ, Ellis LM. 2005b. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027.
20. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME. 2007. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81:427-437.
21. Hussein A, Askar E, Elsaeid M, Schaefer F. 2010. Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol Dial Transplant 25:779-785.
22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
23. Kranenburg O. 2005. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756:81-82.
24. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. 2013. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-1230.
25. Lin LI. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-268.
26. Liu C, Zhang F, Li T, Lu M, Wang L, Yue W, Zhang D. 2012. MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs. BMC Genomics 13:661.
27. Maitland ML, Lou XJ, Ramirez J, Desai AA, McLeod HL, Weichselbaum RR, Ratain MJ. 2010. Vascular endothelial growth factor pathway. Pharmacogenet Genomics 20:346-349.
28. Meunier FA, Osborne SL, Hammond GR, Cooke FT, Parker PJ, Domin J, Schiavo G. 2005. Phosphatidylinositol 3-kinase C2alpha is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol Biol Cell 16:4841-4851.
29. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, Travers M, Potter S, Grundberg E, Small K, Hedman ÅK, Bataille V, et al. 2011. The architecture of gene regulatory variation across multiple human tissues: the MuTHER Study. PLoS Genet 7:e1002003.
30. Noubade R, Krementsov DN, Del Rio R, Thornton T, Nagaleekar V, Saligrama N, Spitzack A, Spach K, Sabio G, Davis RJ, Rincon M, Teuscher C. 2011. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118:3290-3300.
31. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7:359-371.
32. Pang GSY, Wang J, Wang Z, Lee CGL. 2009. Predicting potentially functional SNPs in drug-response genes. Pharmacogenomics 10:639-653.
33. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, et al. 2011. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12:377-386.
34. PharmGKB. 2013. "VEGF signaling pathway." Available at: http://www.pharmgkb.org/do/serve?objId=PA2032&objCls=Pathway#tabview=tab1&subtab=
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575.
36. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, et al. 2012. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31:4559-4566.
37. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, et al. 2011. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43:969-976.
38. Rogers MS, D'Amato RJ. 2012. Common polymorphisms in angiogenesis. Cold Spring Harbor Perspect Med 2(11). pii: a006510.
39. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, et al. 2011a. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219.
40. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, et al. 2011b. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-219.
41. Schneider BP, Shen F, Miller KD. 2012. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 13:e427-e436.
42. Sebio A, Pare L, Paez D, Salazar J, Gonzalez A, Sala N, del Rio E, Martin-Richard M, Tobena M, Barnadas A, Baiget M. 2013. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 23:142-147.
43. Smith AV. 2008. Manipulating HapMap data using HaploView. CSH Protoc 2008:pdb prot5025.
44. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. 2011. A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723-7731.
45. Stephens M, Sloan JS, Robertson PD, Scheet P, Nickerson DA. 2006. Automating sequence-based detection and genotyping of SNPs from diploid samples. Nat Genet 38:375-381.
46. Stevenson M, Nunes T, Sanchez J, Thornton R. 2009. epiR: functions for analysing epidemiological data. Available at: http://CRAN.R-project.org/package=epiR.
47. Teicher BA. 2011. Antiangiogenic agents and targets: a perspective. Biochem Pharmacol 81:6-12.
48. Uriguen L, Gil-Pisa I, Munarriz-Cuezva E, Berrocoso E, Pascau J, Soto-Montenegro ML, Gutierrez-Adan A, Pintado B, Madrigal JLM, Castro E, Sanchez-Blazquez P, Ortega JE, et al. 2013. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Transl Psychiatry 3:e221.
49. Wang J, Ronaghi M, Chong SS, Lee CG. 2011. pfSNP: an integrated potentially functional SNP resource that facilitates hypotheses generation through knowledge syntheses. Hum Mutat 32:19-24.
50. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. 2000. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-1235.
51. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. 2004. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 122:209-215.
52. Zhang W, Dolan ME. 2010. Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics 11:249-256.
53. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, Wu X, He L, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME, et al. 2009. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet 125:81-93.
54. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. 2008. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 82:631-640.